Glypican‐3 distinguishes aggressive from non‐aggressive odontogenic tumors: a preliminary study

Mendes, Ramon Barreto; Dias, Rosane Borges; Figueiredo, Andreia Cristina Leal; Gurgel, Clarissa Araújo Silva; Filho, Manoel Sant’Ana; Melo, Leonardo Araújo; Trierveiler, Marília; Cury, Patrícia Ramos; Leonardi, Rosalia; Santos, Jean Nunes dos

doi:10.1111/jop.12501

Cited by 9 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The other member of the glypican family that has been studied in OTs is glypican-3, which seems to contribute in OT invasiveness and could be considered as a marker to distinguish aggressive from nonaggressive lesions. [ 25 ]…”

Section: Resultsmentioning

confidence: 99%

Proteoglycans as potential biomarkers in odontogenic tumors

Gómez-Herrera

Molina-Frechero

Damián-Matsumura

et al. 2018

J Oral Maxillofac Pathol

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Proteoglycans as potential biomarkers in odontogenic tumors

Gómez-Herrera

Molina-Frechero

Damián-Matsumura

et al. 2018

J Oral Maxillofac Pathol

View full text Add to dashboard Cite

“…[53] Any deletion or mutation of GPC3 can disturb the biological balance between proliferation and apoptosis that ends to tumorigenesis. [54] In specific considerations, only two studies [21,55] in English literature have investigated GPC3 in OTs. They found GPC3 immune staining in the cytoplasm/membranes of the tumor cells the same as this study.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of SOX2 and GPC3 in Ameloblastoma and its malignant counterpart (Ameloblastic Carcinoma)

Hasan

Nagdy

Ibrahim

2021

JST

View full text Add to dashboard Cite

Background: Ameloblastoma is a common benign aggressive odontogenic tumor with a tendency for high recurrence rate. Ameloblastic Carcinoma is the malignant counterpart of Ameloblastoma. However, they are usually difficult to be distinguished from one another. Therefore, using Immunohistochemical markers might be beneficial for diagnosing them accurately.Objective: Evaluation of SOX2 and GPC3 expressions as well as evaluating their roles in the tumorigenesis and the biological behavior of Ameloblastoma and Ameloblastic Carcinoma.Methods: Tissue samples are composed of 34 archived histopathologically confirmed cases of (19 Conventional Ameloblastomas, and 15 Ameloblatic Carcinomas). Sections were subjected to Immunohistochemical staining according to a standard protocol by applying antibodies to SOX2, and GPC3.Results: SOX2 and GPC3 expressions in recurrent Ameloblastoma were significantly higher than non- recurrent cases. Ameloblastic Carcinoma showed the highest immune-reactivity to SOX2 and GPC3 compared to the Conventional Ameloblastoma. Desmoplastic Ameloblastoma showed the highest scores of SOX2 and GPC3 compared to the other subtypes.Conclusions: SOX2 and GPC3 can be used as a panel for diagnosing the aggressive and the malignant odontogenic tumors accurately. Desmoplastic Ameloblastoma behaves more aggressively than other Conventional Ameloblastoma subtypes.

show abstract

“…In the case of the stimulation of Wnt signaling, it has been proposed that the stimulatory mechanism is based on the ability of glypicans to facilitate and/or stabilize the interaction of Wnts with their signaling receptors, the Frizzled proteins. This hypothesis is based on the finding that glypicans can bind to Wnts and to Frizzleds [9] and that transfection of glypicans increases the Wnt-binding capacity of the transfected cells [9]. In the case of Hhs, it has been recently reported that GPC3 inhibits their signaling during development by competing with Patched, the Hh receptor, for Hh binding [11].…”

Section: Mechanism Of Actionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Glypicans - A Brief Review

Gupta

2019

J. Anal. Oncol.

View full text Add to dashboard Cite

Glypicans (GPCs) are a family of proteoglycans that are bound to the cell surface by a glycosylphosphatidylinositol anchor. Six glypicans have been found in the mammalian genome (GPC1 to GPC6). Glypicans can be released from the cell surface by a lipase called Notum, and most of them are subjected to endoproteolytic cleavage by furin-like convertases. In vivo evidence published so far indicates that the main function of membrane-attached glypicans is to regulate the signaling of Wnts, Hedgehogs, fibroblast growth factors and bone morphogenetic proteins (BMPs). Surprisingly, the regulatory activity of glypicans in the Wnt, Hedgehog and BMP signaling pathways is only partially dependent on the heparan sulfate chains. It is obvious that our knowledge of glypican functions is still very limited despite the recent advances. A better understanding of these functions will make a significant contribution to the study of signaling pathways that play a very important role in developmental morphogenesis and several human diseases, including cancer.

show abstract

Glypican‐3 distinguishes aggressive from non‐aggressive odontogenic tumors: a preliminary study

Abstract: This provided insights into the presence of glypican-3 in odontogenic tumors. This protein distinguished aggressive from non-aggressive odontogenic tumors.

Cited by 9 publications

References 30 publications

Proteoglycans as potential biomarkers in odontogenic tumors

Proteoglycans as potential biomarkers in odontogenic tumors

Prognostic significance of SOX2 and GPC3 in Ameloblastoma and its malignant counterpart (Ameloblastic Carcinoma)

Glypicans - A Brief Review

Contact Info

Product

Resources

About